November 25, 2020 -- Covaxx, a subsidiary of United Biomedical, has received purchase commitments of more than 140 million doses of its UB-612 COVID-19 vaccine, totaling over $2.8 billion. The vaccine will be delivered to multiple countries including Brazil, Ecuador, and Peru.
These commitments follow the initiation of human trials in Taiwan and an agreement with Diagnosticos da America to conduct phase II/III clinical trials and distribute the vaccine within Brazil. In October, the company announced a global logistic partnership with Maersk for transportation and supply chain services to deliver UB-612 around the world.
Covaxx's UB-612 is a multitope, synthetic peptide-based vaccine candidate. Covaxx is currently completing phase I clinical trials of UB-612 in Taiwan and has an agreement with the University of Nebraska Medical Center, home of the National Pandemic Center, to also conduct trials in the U.S.
The vaccine candidate is boostable, meaning the technology can effectively boost repeatedly without side effects, and it is stable at 2-8° C, so it can be distributed and stored at normal refrigeration, according to the company. Clinical efficacy data is expected to be available in the next few months.
The company plans to manufacture up to 100 million doses in the first half of 2021 and up to 1 billion by the end of 2021.